Fig. 1: Kaplan–Meier curves for TTD, OS, and PFS for comparisons between the 1 L pralsetinib trial cohort and 1 L pembrolizumab cohort, and 1 L pralsetinib trial cohort and 1 L pembrolizumab with chemotherapy cohort. | Nature Communications

Fig. 1: Kaplan–Meier curves for TTD, OS, and PFS for comparisons between the 1 L pralsetinib trial cohort and 1 L pembrolizumab cohort, and 1 L pralsetinib trial cohort and 1 L pembrolizumab with chemotherapy cohort.

From: Addressing challenges with real-world synthetic control arms to demonstrate the comparative effectiveness of Pralsetinib in non-small cell lung cancer

Fig. 1

A–C The Kaplan–Meier curves are for each endpoint TTD, OS, and PFS panels respectively for the comparison between 1 L pralsetinib versus 1 L pembrolizumab (ESS = 109 for the pralsetinib cohort, and ESS = 115 for the pembrolizumab cohort), and D–F for the comparison between 1 L pralsetinib versus 1 L pembrolizumab with chemotherapy after IPTW-adjustment (ESS = 109 for the pralsetinib cohort, and ESS = 217 for the pembrolizumab with chemotherapy cohort); the median OS for the pralsetinib cohorts could not be computed.

Back to article page